ABSTRACT
PRIMARY OBJECTIVE: Assess the test-re-test reliability of walking speed, step length and step width measurement in people with traumatic brain injury (TBI). RESEARCH DESIGN: Repeated measures (two test occasions). METHODS: Thirteen people with TBI completed four comfortable and four fast-paced walking trials of the 10 m walk test and two trials of the 6-minute walk test (6MWT). Walking speed, step length and step width were measured during the 10 m walk test and walking distance and average speed were measured during the 6MWT. The tests were repeated 1-week later. MAIN RESULTS: Walking speed and distance showed excellent test-re-test reliability, with an intra-class correlation coefficient (ICC) of 0.95-0.96. Reliability was also high for step length and width measurement (ICC 0.91-0.98). CONCLUSIONS: This test-re-test reliability means that walking speed and distance and step length and width can be used by physiotherapists to monitor improvements in walking after TBI.
Subject(s)
Brain Injuries/psychology , Gait , Neuropsychological Tests , Walking , Adult , Analysis of Variance , Brain Injuries/rehabilitation , Female , Humans , Male , Pilot Projects , Reproducibility of ResultsABSTRACT
OBJECTIVE: To assess the inter-rater reliability and concurrent validity of walking speed measurement after traumatic brain injury. DESIGN: Twelve subjects each completed five comfortably paced and five fast-paced walking trials. Walking speed was measured simultaneously by five observers using a stopwatch (clinical procedure) and by infrared timing gates (gold standard). SETTING: Brain injury rehabilitation unit. SUBJECTS: People with traumatic brain injury who could walk independently and were participating in a rehabilitation programme. MAIN OUTCOME MEASURES: Walking speed over a 10-metre distance. RESULTS: The inter-rater reliability of walking speed measured using a stopwatch was very high, with an intraclass correlation coefficient of at least 0.998 for both comfortable and fast-paced tests. Concurrent validity was excellent for comfortable and fast tests, with perfect correlations between the stopwatch and infrared timing gate measurement procedures. CONCLUSIONS: Physiotherapists can use a stopwatch as a reliable and valid measurement tool to quantify walking speed over a short distance at both comfortable and fast paces in people who have sustained traumatic brain injuries.
Subject(s)
Brain Injuries/rehabilitation , Exercise Test/instrumentation , Time and Motion Studies , Walking/physiology , Adult , Brain Injuries/physiopathology , Female , Humans , Male , Reproducibility of ResultsABSTRACT
PURPOSE: To determine the inter-rater reliability and concurrent validity of step length and step width measurement after traumatic brain injury. METHOD: Twelve people with traumatic brain injury completed six comfortable and six fast paced walking trials over a 10 m distance. Step length and step width were measured by five observers using two procedures. First, using pens taped on the subjects' heels which marked the floor at each heel strike and a tape measure. Second, by videotaping the subjects' feet as they walked on a mat marked with 5 cm grids and using a computer program to digitize foot position and calculate step length and width. RESULTS: The inter-rater reliability of step length and width measurements was very high, with intraclass correlation coefficients between 0.94 and 1.00, for both procedures. Concurrent validity was excellent, with correlations between the procedures ranging from 0.93 to 1.00. However, attaching pens to the heels did cause a slight reduction in right step length and walking speed when walking at a fast or comfortable pace, respectively. CONCLUSIONS: Assessing step length and width using pens taped to the subjects' heels and a tape measure is a reliable and valid clinical measure after traumatic brain injury.
Subject(s)
Brain Injuries/rehabilitation , Gait , Adult , Female , Humans , Male , Observer Variation , Physical Therapy Modalities/methods , Reproducibility of Results , WalkingABSTRACT
An 18-month-old girl is reported in whom marked unilateral breast enlargement occurred after 4 weeks of cimetidine therapy. After withdrawal of the drug the enlargement rapidly disappeared. This observation points to cimetidine as a possible cause of premature thelarche. Cimetidine, a selective H2 receptor blocking agent, is known to cause gynaecomastia in males. This effect seems related to elevated plasma oestrogens, gonadotropins, or to binding of the drug to androgen receptors. Ranitidine, a much more potent selective H2 receptor blocker, does not cause gynaecomastia and seems therefore preferable to cimetidine.
